< Back to previous page
Project
Accelerating availability and access to typhoid conjugate vaccines (TyVac).
To date, only a handful of studies have generated cost-effectiveness estimates for Vi-polysaccharidevaccines, and all of these have been based on static modeling approaches. We will conduct cost-effectivenessanalyses (CEAs) to assess the costs and effects of new and existing TCV vaccinationstrategies compared to no vaccination from the health care perspective based on dynamic models. Wewill build off of CEAs currently being led by Dr. Pitzer (funded by BMGF) by incorporating primary datafrom sentinel hospitals in the surveillance sites to inform immunization rates and estimates of costs ofvaccine administration and disease.
Date:1 Jan 2021 → 31 Oct 2021
Keywords:HEALTH ECONOMICS
Disciplines:Health economy